[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"countryName\":\"Qatar\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":682},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,41,0,25,[9,48,79,105,132,157,188,210,233,256,283,308,332,361,390,411,437,459,487,513,544,574,604,631,655],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100508709","air-pollution-and-cardiovascular-disease-in-qatar-an-interventional-study-to-reduce-blood-pressure-100508709",false,"NCT05903950","Air Pollution and Cardiovascular Disease in Qatar: an Interventional Study to Reduce Blood Pressure","Air Pollution and Cardiovascular Disease in Qatar: an Interventional Study to Reduce Blood Pressure: the APCIQ-BP Trial","APCIQ-BP","Inclusion Criteria:\n\n* Non-smokers (100% abstinence from use of any smoking or vaping product during the prior year)\n* Age ≥18 and less than 60 years old\n* Living in a single residence (home, apartment) located anywhere in Qatar\n* Mild systolic hypertension: screening visit systolic BP 130 to 159 mm Hg (off treatment or taking ≤ 2 BP medications that have been stable without changes during prior 4 weeks) plus ≥ 2 more additional criteria for the metabolic syndrome:\n\n  * Waist circumference ≥102 cm if male and ≥88 cm if female\n  * Fasting triglycerides ≥150 mg\u002FdL (or taking a triglyceride-lowering medication)\n  * HDL-C ≤ 40 mg\u002FdL if male and ≤ 50 mg\u002FdL if female (or taking an HDL-raising medication),\n  * Fasting glucose ≥100 mg\u002FdL\n\nExclusion Criteria:\n\n* Pregnancy (self-reported)\n* Screening visit urine positive for cotinine (NicAlert \\>100 ng\u002FmL)\n* Living with an active smoker who smokes indoors (by self-report)\n* High risk conditions that prohibit allowing home BP to be \\>130\u002F80 mm Hg during the10-week trial including any cardiovascular disease (coronary artery disease, prior stroke, heart failure, peripheral arterial disease, aneurysm) or ≥ stage 3 kidney disease (estimated glomerular filtration rate \\\u003C 60 ml\u002Fmin)\n* A medical condition placing the participant at risk from participation (per investigators)\n* Expected overnight travel outside their residence during the study\n* HEPA filter within the air conditioners of the residence (self-reported) or individual use of HEPA filter\n* Unable to comprehend\u002Fsign an informed consent\n* Lung disease requiring oxygen\n* Cancer receiving treatment\n* Screening visit: BP ≥160\u002F100 mm Hg or fasting blood glucose ≥126 mg\u002FdL and confirmed diabetes with follow-up HbA1c ≥6.5%. If glucose is elevated ≥126 mg\u002FdL but HbA1c\\\u003C6.5%, they could still participate.\n* Medication changes in past 4 weeks. If participants are on medications for high BP or hyperlipidemia, they will need to have had stable therapy during prior 10 weeks with no planned changes during the study\n* Left upper arm circumference \\>17 inches as this will make BP levels inaccurate with the home monitor used\n* Acute illness or infectious symptoms within the prior 4 weeks.","ALL","18 Years","60 Years",{"count":22,"type":23},100,"ESTIMATED","INTERVENTIONAL",[26],"NA","The main objective is to determine if in-home portable air cleaners provide persistent reductions in PM2.5 exposures and improvements in systolic blood pressure and biochemical parameters over 4-weeks in patients with metabolic syndrome residing in Qatar.",[29,30],"Hypertension, Systolic","Metabolic Syndrome",[32,33,34],"hypertension","metabolic syndrome","air pollution","RECRUITING","2026-08-18",{"date":38,"type":39},"2026-08-20","ACTUAL",{"date":41,"type":39},"2024-11-03",{"date":43,"type":23},"2026-12",{"name":45,"class":46},"Weill Cornell Medical College in Qatar","OTHER",1,{"id":49,"slug":50,"hasResults":12,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":18,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":24,"phases":60,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100585624","treatment-outcomes-of-pulpotomy-versus-pulpectomy-in-vital-primary-molars-diagnosed-with-irreversible-pulpitis-100585624","NCT06904781","Treatment Outcomes of Pulpotomy Versus Pulpectomy in Vital Primary Molars Diagnosed With Irreversible Pulpitis","Treatment Outcomes of Pulpotomy Versus Pulpectomy in Vital Primary Molars Diagnosed With Symptomatic Irreversible Pulpitis: A Non-inferiority Randomised Controlled Trial","Inclusion Criteria:\n\n1. Healthy (ASA I and II) co-operative children (Frankl Scale + and ++) between the ages of four and nine years.\n2. Participants have symptoms typical of irreversible pulpitis in one of the primary molars.\n3. The pulp of the affected primary molar is vital.\n4. Radicular pulp health is confirmed by attainment of radicular pulp haemostasis within 6 minutes of coronal pulp amputation.\n5. The affected primary molars can be restored with full coverage stainless steel crowns.\n6. Any physiologic root resorption, if present, is less than ⅓ the root length.\n\nExclusion Criteria:\n\n1. Clinical examination of affected primary molar reveals signs of pulpal infection (e.g. pathologic tooth mobility, parulis\u002Ffistula, or soft tissue swelling).\n2. Pre-operative periapical radiograph suggests presence of periapical radiolucency or pathologic root resorption.\n3. Visual examination of pulp tissue after deroofing reveals signs of necrosis (e.g. avascular\u002Fminimally bleeding pulp tissue or yellowish necrotic areas\u002Fpurulent exudate).\n4. Signs of extensive radicular pulp inflammation i.e., root pulp bleeding continues even after 6-min.\n5. Parents not willing to place full coverage crowns post-treatment.\n6. Clinical diagnosis of irreversible pulpitis between two adjacent primary molars is not sharply defined.\n7. Unable to perform clinical procedure under rubber dam",true,"4 Years","9 Years",{"count":59,"type":23},80,[26],"This randomised controlled trial aims to compare treatment outcomes between pulpotomy and pulpectomy when used to treat vital primary molars diagnosed with symptomatic irreversible pulpitis. Compared to the standard pulpectomy treatment, pulpotomy is a technically simpler procedure, less time consuming, easier for young patients to tolerate, while retaining the proprioceptive sensation of the tooth - all important advantages when treating young children.",[63],"Irreversible Pulpitis",[65,66,67,68],"Pulpectomy","Pulpotomy","Vital primary molars","Irreversible pulpitis","2026-08-11",{"date":71,"type":39},"2026-08-13",{"date":73,"type":39},"2025-08-01",{"date":75,"type":23},"2028-06-30",{"name":77,"class":46},"Qatar University",2,{"id":80,"slug":81,"hasResults":12,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":12,"sex":86,"minAge":19,"maxAge":4,"enrollmentInfo":87,"targetDuration":89,"studyType":90,"phases":4,"briefSummary":91,"conditions":92,"keywords":95,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":97,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":104},"100480992","bph-global-registry-100480992","NCT05543200","BPH Global Registry","A Global Registry of Treatments and Outcomes for Benign Prostatic Hyperplasia","Inclusion Criteria:\n\n* Primary diagnosis of BPH with LUTS with prescribed medical treatment or surgical intervention\n\nExclusion Criteria:\n\n* Non-symptomatic BPH\n* No treatment prescribed for BPH","MALE",{"count":88,"type":23},7500,"3 Years","OBSERVATIONAL","Benign prostatic hyperplasia (BPH) is one of the most common performed surgical procedures in urology. Over the past few decades there have been an increasing development of newer surgical treatment options. Additionally, the outcome parameters for BPH treatments have been standardized. While data are available for the initial pivotal studies, post-market release data are lacking. Under the umbrella of uCARE, we have started a prospective, ongoing international registry for recording demographics and outcomes for patients undergoing surgical treatments for BPH.",[93,94],"Benign Prostatic Hyperplasia","Lower Urinary Tract Symptoms",[96],"BPH, Registry, LUTS",{"date":71,"type":39},{"date":99,"type":39},"2023-03-13",{"date":101,"type":23},"2028-12",{"name":103,"class":46},"Société Internationale d'Urologie",30,{"id":106,"slug":107,"hasResults":12,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":12,"sex":18,"minAge":113,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":24,"phases":117,"briefSummary":119,"conditions":120,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":131},"100505485","phase-4-a-study-evaluating-the-effectiveness-and-safety-of-risdiplam-administered-in-pediatric-patients-with-spinal-muscular-atrophy-who-experienced-a-plateau-or-decline-in-function-after-gene-therapy-100505485","NCT05861999","A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy","A Phase IV Open-Label Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy","HINALEA 2","Inclusion Criteria:\n\n* \\\u003C2 years of age at the time of informed consent\n* Confirmed diagnosis of 5q-autosomal recessive SMA, including genetic confirmation of homozygous deletion or compound heterozygosity predictive of loss of function of the Survival of Motor Neuron 1 (SMN1) gene\n* Confirmed presence of two SMN2 gene copies as documented through laboratory testing\n* Administration of onasemnogene abeparvovec pre-symptomatically or post-symptomatically\n* Has received onasemnogene abeparvovec for SMA no less than 13 weeks prior to enrollment\n* If treated with risdiplam prior to onasemnogene abeparvovec, risdiplam treatment must not have exceeded 3 weeks and must be discontinued 1 day prior to onasemnogene abeparvovec administration.\n* In the opinion of the investigator, has demonstrated a plateau or decline in function post-gene therapy (with a duration of 26 weeks or less) documented by 2 individual time points in the functions as follows: swallowing AND one additional function\u002Fability (respiratory, motor function, other) per appropriate expectation.\n\nExclusion Criteria:\n\n* Previous or current enrolment in investigational study prior to initiation of study treatment\n* Any unresolved standard-of-care laboratory abnormalities per the onasemnogene abeparvovec prescribing information\n* Concomitant or previous administration of an SMN2-targeting antisense oligonucleotide\n* Concomitant or previous use of an anti-myostatin agent\n* Participants requiring invasive ventilation or tracheostomy\n* Presence of feeding tube and an OrSAT score of 0\n* Hospitalization for pulmonary event within the last 2 months, or any planned hospitalization at the time of screening\n* Any major illness requiring hospitalization within 1 month before the screening examination or any febrile illness within 1 week prior to screening and up to first dose administration.","3 Months","24 Months",{"count":116,"type":23},28,[118],"PHASE4","This is an open-label, single-arm, multicenter clinical study to evaluate the effectiveness and safety of risdiplam administered in pediatric participants with SMA and 2 SMN2 copies who previously received onasemnogene abeparvovec and experience a plateau or decline in function. Participants to be enrolled are children \\\u003C2 years of age genetically diagnosed with SMA.",[121],"Muscular Atrophy, Spinal","2026-08-10",{"date":69,"type":39},{"date":125,"type":39},"2024-08-14",{"date":127,"type":23},"2029-03-31",{"name":129,"class":130},"Hoffmann-La Roche","INDUSTRY",19,{"id":133,"slug":134,"hasResults":12,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":12,"sex":140,"minAge":19,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":90,"phases":4,"briefSummary":143,"conditions":144,"keywords":146,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":154,"locationsCount":156},"100640673","beyond-study-a-multicentre-prospective-observational-study-of-real-world-treatment-patterns-and-outcomes-of-trastuzumab-deruxtecan-in-patients-with-hr-positive-her2-low-or-ultra-low-metastatic-breast-cancer-previously-treated-with-endocrine-therapy-100640673","NCT07597993","BEYOND Study: A Multicentre, Prospective, Observational Study of Real-world Treatment Patterns and Outcomes of Trastuzumab Deruxtecan in Patients With HR Positive, HER2-low or Ultra-low Metastatic Breast Cancer Previously Treated With Endocrine Therapy","A Multicentre, Prospective, Observational Study of Real-world Treatment Patterns and Outcomes of Trastuzumab Deruxtecan in Patients With HR Positive, HER2-low or Ultra-low Metastatic Breast Cancer Previously Treated With Endocrine Therapy","BEYOND","Inclusion Criteria:\n\n* -Female patients aged ≥18 years old at the time of T-DXd initiation\n* Patients with a confirmed histological or cytologically based diagnosis of HR-positive mBC.\n* Patients who were classified as HER2-low or HER2-ultralow mBC confirmed by the closest locally obtained HER2 test prior to or on the index date, and who meet the following definitions:\n* HER2-low status defined as IHC scores 1+ and 2+ without ISH gene amplification based on the pathology report.\n* HER2-ultralow status defined as IHC 0 with membrane staining based on the pathology report.\n* Patient who received at least one prior line of ET (± targeted therapy) in the metastatic setting.\n* Patients who are chemotherapy-naïve in the metastatic setting.\n* Patients who initiated T-DXd up to 30 days before the signature of the ICF. The decision to initiate T-DXd must be made independently by treating physicians as part of routine clinical practice.\n* Patients are willing to sign the written ICF, indicating that they understand the purpose of the study and procedures required for participation.\n\nExclusion Criteria:\n\n* -Patients with a history of other malignancies, other than basal cell carcinoma of the skin and squamous cell carcinoma of the skin.\n* Patients who received prior chemotherapy in the metastatic setting.\n* Patients with Eastern Cooperative Oncology Group (ECOG) status ≥2 or missing ECOG status at the time of initiation of T-DXd (index date).\n* Patients with a history of participation in another clinical trial in the metastatic setting.\n* Female patient with current or planned pregnancy, or breastfeeding.","FEMALE",{"count":142,"type":23},109,"BEYOND study is designed to generate the first real-world data from GCC countries on the patient characteristics, treatment patterns, survival outcomes, and safety of T-DXd in patients with HRpositive,HER2-low or HER2-ultralow mBC previously treated with ET. The evidence generated will help to optimise treatment strategies, inform clinical guidelines, and ultimately improve outcomes for patients with mBC across the region.",[145],"Breast Cancer",[147,148],"breast cancer","Trastuzumab Deruxtecan","2026-08-06",{"date":122,"type":39},{"date":152,"type":39},"2026-07-12",{"date":127,"type":23},{"name":155,"class":130},"AstraZeneca",9,{"id":158,"slug":159,"hasResults":12,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":12,"sex":18,"minAge":165,"maxAge":166,"enrollmentInfo":167,"targetDuration":4,"studyType":24,"phases":169,"briefSummary":171,"conditions":172,"keywords":174,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":187},"100535073","phase-3-a-study-to-investigate-efficacy-and-safety-of-pegtibatinase-compared-with-placebo-in-participants-12-to-65-years-of-age-with-classical-homocystinuria-hcu-due-to-cystathionine-beta-synthase-deficiency-receiving-standard-of-care-treatment-100535073","NCT06247085","A Study to Investigate Efficacy and Safety of Pegtibatinase Compared With Placebo in Participants ≥12 to ≤65 Years of Age With Classical Homocystinuria (HCU) Due to Cystathionine Beta Synthase Deficiency Receiving Standard of Care Treatment","A Phase 3, Parallel-Group Treatment, Blinded, Randomized, Placebo-Controlled Study To Assess The Efficacy And Safety Of Pegtibatinase Administered Subcutaneously In Addition To Standard Of Care In Participants With Classical Homocystinuria Due To Cystathionine Beta Synthase Deficiency (HARMONY)","HARMONY","Inclusion Criteria:\n\n* Must be ≥12 to ≤65 years of age, at the time of signing the informed consent\n* Must have a diagnosis of classical HCU based on clinical, biochemical, and\u002For molecular genetic testing\n* Plasma tHcy ≥80 µM at Screening visit, with allowance for up to 18 participants who may be enrolled with a Screening plasma tHcy ≥50 to \\\u003C80 µM\n* Participants who can become pregnant must have a negative pregnancy test before starting the study and must use a highly effective form of birth control (less than 1% risk of pregnancy per year) during the study and for at least 4 weeks after the last dose.\n* Willing to maintain a generally stable diet for the duration of the study (unless changes are required based on medical\u002Fsafety reasons)\n* Willing to maintain generally stable intake and doses of betaine, pyridoxine, and medical food for the duration of the study (unless changes are required based on medical\u002Fsafety reasons)\n\nExclusion Criteria:\n\n* Diagnosis of Marfan syndrome, methylenetetrahydrofolate reductase (MTHFR) deficiency, or disorder of cobalamin metabolism\n* Concurrent disease or condition (eg, history or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurological, oncologic, or psychiatric disease) that would interfere with study participation or safety (excluding complications of HCU).\n* History of major thrombotic event (eg, cerebrovascular accident, myocardial infarction, pulmonary embolism) in the previous 6 months.\n* Body weight ≥160 kg.\n* Use or planned use of any injectable drugs containing PEG (excluding PEG-containing vaccines)\n* Any previous exposure to pegtibatinase and\u002For previous participation in a clinical study that included administration of pegtibatinase or pegtarviliase\n* Prior severe immune reaction to a PEG-containing product","12 Years","65 Years",{"count":168,"type":23},70,[170],"PHASE3","The purpose of this study is to measure efficacy and safety of pegtibatinase treatment compared with placebo in participants with classical HCU receiving standard of care. Study details include:\n\n* Total Study duration: up to 38 weeks\n* Screening:\n\n  * Initial Screening duration: up to 4 weeks\n  * Pre-treatment Diet Standardization Period duration: up to 6 weeks\n* Blinded Treatment Duration: 24 weeks\n\n  * 2-week blinded dose titration period\n  * 22-week blinded assessment period\n* Safety Follow-Up: 4 weeks after last dose (as applicable for those not enrolling in the long term extension study, ENSEMBLE)",[173],"Homocystinuria",[175,176,177],"HCU","cystathionine beta synthase deficiency","Classical Homocystinuria","2026-08-05",{"date":180,"type":39},"2026-08-07",{"date":182,"type":39},"2023-12-28",{"date":184,"type":23},"2027-09",{"name":186,"class":130},"Travere Therapeutics, Inc.",52,{"id":189,"slug":190,"hasResults":12,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":12,"sex":18,"minAge":195,"maxAge":166,"enrollmentInfo":196,"targetDuration":4,"studyType":24,"phases":198,"briefSummary":201,"conditions":202,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":203,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":209},"100316977","pegtibatinase-as-a-treatment-for-patients-with-classical-homocystinuria-hcu-also-known-as-the-compose-study-100316977","NCT03406611","Pegtibatinase as a Treatment for Patients With Classical Homocystinuria (HCU) (Also Known as the COMPOSE Study)","A Phase 1\u002F2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Effects on Clinical Outcomes of Pegtibatinase (TVT-058) Administered Subcutaneously in Subjects With Cystathionine Beta Synthase-Deficient Homocystinuria (COMPOSE)","Inclusion Criteria:\n\n* Age\n\n  * Cohort 7 (currently enrolling): ≥5 to \\\u003C12 years of age.\n  * Completed Cohorts 1-6: ≥12 to 65 years of age.\n* Diagnosis of classical homocystinuria (HCU)\n\n  * Cohort 7 (currently enrolling): Diagnosis based on clinical, biochemical, and\u002For molecular genetic testing.\n  * Completed Cohorts 1-6: Genetically confirmed cystathionine beta-synthase (CBS)-deficient HCU.\n* Plasma total homocysteine (tHcy)\n\n  * Cohort 7 (currently enrolling): Plasma tHcy ≥50 μM at Screening.\n  * Completed Cohorts 1-6: Plasma tHcy ≥50 μM at Screening and documented historical plasma tHcy ≥80 μM.\n* Willing and able (or parent\u002Flegal guardian willing and able) to provide informed consent\u002Fassent and comply with study procedures.\n* Willing to maintain a generally stable standard-of-care treatment regimen, including dietary management and HCU-related therapies, unless changes are medically necessary.\n* Participants of childbearing potential must have a negative pregnancy test before study treatment and agree to use protocol-specified contraception, if applicable.\n\nExclusion Criteria:\n\nCohort 7 only:\n\n* Diagnosis of Marfan syndrome, methylenetetrahydrofolate reductase (MTHFR) deficiency, or a disorder of cobalamin metabolism.\n* History of a major thrombotic event within the previous 6 months.\n* Body weight \\\u003C15 kg.\n\nAll Cohorts:\n\n* Previous treatment with pegtibatinase or pegtarviliase)\n* Participation in a pegtibatinase clinical study.\n* Receipt of another investigational drug or investigational medical device within 30 days before Screening or planned use during study participation.\n* Use of injectable polyethylene glycol (PEG)-containing medications (other than pegtibatinase or PEG-containing vaccines) within 3 months before Screening or during study participation.\n* Known hypersensitivity to pegtibatinase or a history of severe hypersensitivity to a PEG-containing product.\n* Active HIV, hepatitis B, or hepatitis C infection.\n* History of organ transplantation or immunosuppressive therapy.\n* Clinically significant medical conditions that could interfere with study participation or participant safety.\n* Pregnant or breastfeeding, or planning to become pregnant during study participation.\n* Major surgery planned during the study period.\n* Any condition that could prevent the participant from complying with study procedures or completing the study.","5 Years",{"count":197,"type":23},39,[199,200],"PHASE1","PHASE2","Researchers are looking for a better way to treat people who have classical homocystinuria (HCU), a rare condition that is passed down by parents (or \"genetic condition\"). It is caused by changes in the cystathionine beta-synthase (or \"CBS\") gene and prevents an enzyme from working correctly in the body. This enzyme breaks down a substance called homocysteine (from dietary methionine found in protein) and keeps both homocysteine and methionine at normal levels. When this enzyme is not working, homocysteine and methionine build up in the blood, which spreads into different tissues of the body and stops these body tissues from working normally.\n\nPeople with HCU can experience problems with vision, bones, blood vessels, and cognitive function (the ability to think, learn, and remember). Treatments available for HCU, such as a low protein diet and betaine (Cystadane®), help reduce homocysteine levels. The diet is a low methionine diet and a methionine-free protein supplement (a product that provides extra protein to help meet daily protein needs). These treatments are either not sufficient or are hard to take for many patients.\n\nPegtibatinase was developed by scientists to be a version of the CBS enzyme that can be given to people with HCU. Researchers believe that giving pegtibatinase to people with HCU already getting medical treatment (or \"standard of care\") may reduce their homocysteine levels.\n\nThis study is split into 7 different groups getting different amounts of drug. The first 6 groups have already finished the study.\n\nGroup 7 plans to enroll participants from the US (virtual and in-person), France, and Qatar.",[173],{"date":122,"type":39},{"date":205,"type":39},"2019-01-22",{"date":207,"type":23},"2027-07",{"name":186,"class":130},12,{"id":211,"slug":212,"hasResults":12,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":216,"eligibilityCriteria":217,"healthyVolunteers":12,"sex":18,"minAge":165,"maxAge":4,"enrollmentInfo":218,"targetDuration":4,"studyType":90,"phases":4,"briefSummary":220,"conditions":221,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":232},"100628893","the-impact-of-dupilumab-treatment-on-anxiety-and-depression-symptoms-in-patients-with-moderate-to-severe-atopic-dermatitis-100628893","NCT07467564","The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatitis","The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatitis in Gulf Countries","DERMIND-AD","Inclusion Criteria:\n\n* Participants who have moderate to severe AD with signs and symptoms of anxiety and\u002For depression.\n* Participants who initiate dupilumab therapy within 30 days of enrolment, based on the treating physician's decision, independently of study participation\n* Participants and\u002For their legally approved representatives (LAR in case of the minor subject) must agree to sign an informed consent or an assent.\n\nExclusion Criteria:\n\n* Females who are pregnant, lactating, or planning\u002Fintending to be pregnant in the next 6 months.\n* Participants who are participating in another trial.\n* Participants with active chronic or acute infection requiring systemic treatment.\n* Participants who are diagnosed with active endoparasite infection or are suspected of being at high risk of infection.\n* Participants with human immunodeficiency virus (HIV), hepatitis B or C, malignancy, or other concomitant illnesses.\n* Participants on antidepressants\u002Fanti-anxiety within 6 months of enrolment or those who are planning to receive antidepressants\u002Fanti-anxiety. In addition, those who will use antidepressants\u002Fanti-anxiety medications throughout the study will be excluded from the analysis.\n\nThe above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.",{"count":219,"type":23},184,"This study aims to assess the impact of dupilumab on the mental health and quality of life of moderate-to-severe Atopic Dermatitis (AD) patients. The study will recruit participants from AD patients who are already receiving dupilumab treatment. The study enrollment period will be about 9 months with each of the participants undergoing a 6-month observational study period.",[222],"Atopic Dermatitis","2026-07-27",{"date":225,"type":39},"2026-07-28",{"date":227,"type":39},"2026-02-24",{"date":229,"type":23},"2027-05-24",{"name":231,"class":130},"Sanofi",7,{"id":234,"slug":235,"hasResults":12,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":4,"eligibilityCriteria":239,"healthyVolunteers":12,"sex":18,"minAge":240,"maxAge":241,"enrollmentInfo":242,"targetDuration":4,"studyType":24,"phases":244,"briefSummary":245,"conditions":246,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":248,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":255},"100498175","phase-2-patiromer-for-treatment-of-hyperkalaemia-in-children-under-12-years-of-age-100498175","NCT05766839","Patiromer for Treatment of Hyperkalaemia in Children Under 12 Years of Age","A 2-Part, Open-Label, Phase 2, Multiple Dose Study to Evaluate the Pharmacodynamic Effects, Safety, and Tolerability of Patiromer in Children Under 12 Years of Age With Hyperkalaemia (EMERALD2)","Inclusion Criteria:\n\n* Paediatric participants (\\\u003C12 years of age) with hyperkalaemia at screening.\n* Participant's age should not reach 12 years during the 28 days of the pharmacodynamic\u002Fdose-ranging period.\n* Participant is able to receive regular external feeding and medication, including via tubes, i.e., percutaneous endoscopic gastrostomy (PEG) or entero-gastric feeding tube.\n* At screening\u002Fbaseline, the results from 2 separate and consecutive potassium assessments using the same measurement method (whole blood, plasma, or serum) need to be above the age-appropriate upper limit of normal (ULN).\n* If taking any renin-angiotensin aldosterone system inhibitors (RAASi), beta blockers, fludrocortisone, or diuretic medications, must be on a stable dose for at least 14 days prior to screening.\n* Parent(s) or legally authorised representative(s) or another appropriate person delegated by the legally authorised representatives must be available to help the study-site personnel ensure follow-up; accompany the participant to the study site on each assessment day; accurately and reliably dispense investigational product as directed.\n* Females of childbearing potential must be non-lactating, must have a negative pregnancy test at screening, and must have used an effective, acceptable form of contraception (e.g., abstinence) for at least 1 month before patiromer administration. Females of childbearing potential must agree to continue using contraception throughout the study and for 1 month after the last dose of patiromer.\n* If undergoing peritoneal dialysis, participants must be on a stable treatment plan for a minimum of 4 weeks prior to screening, or at least 8 weeks prior to screening if newly initiated on peritoneal dialysis.\n\nExclusion Criteria:\n\n* Preterm birth infants with \\\u003C37 weeks of gestation cannot be included in Cohort 3.\n* Participants who due to their general condition, e.g., anaemia or low body weight, are not suitable to have blood volume withdrawn.\n* Any of the following renal conditions: maintenance haemodialysis, renal artery stenosis, and acute kidney injury (defined by 2012 Kidney Disease Improving Global Outcomes) or a history of acute renal insufficiency in the past 3 months. Note: Chronic kidney disease (CKD) is not excluded.\n* A history of or current diagnosis of a severe gastrointestinal (GI) diagnosis or surgery that could affect GI transit of the drug (delayed gastric emptying), such as a severe swallowing disorder, severe gastroesophageal reflux, uncorrected pyloric stenosis, intussusception, any other intestinal obstruction (e.g., Hirschsprung disease, chronic intestinal pseudo-obstruction, clinically significant postsurgical abdominal adhesions) or any gut-shortening surgical procedure prior to screening. Pre-gastric above-mentioned pathologies may be disregarded in case of existence of a PEG or entero-gastric feeding tube, as the PEG or entero-gastric feeding tube will serve for nutrition and investigational product administration.\n* Active cancer, currently on cancer treatment, or history of cancer in the past 2 years (except for non-melanoma skin cancer).\n* Scheduled for kidney transplant procedure during the first 28 days after Day 1.\n* History of sudden infant death in a sibling (only for participants \\\u003C2 years of age at screening).\n* Use of the following medications if doses have not been stable for at least 14 days prior to screening or if doses are anticipated to change during the 4-week pharmacodynamic\u002F\n* Dose-ranging period: digoxin, bronchodilators, theophylline, heparins (including low molecular heparins), tacrolimus, mycophenolate mofetil, cyclosporine, trimethoprim, or cotrimoxazole.\n* Use of any investigational product for an unapproved indication within 30 days prior to screening or within 5 half-lives, whichever is longer.\n* Known hypersensitivity to patiromer or its components.\n* If the child is being breastfed:\n\n  1. There is suspicion of current alcohol or substance misuse\u002Fabuse in breastfeeding mother.\n  2. The breastfeeding mother is taking potassium supplements\n* Other protocol defined Inclusion\u002FExclusion criteria may apply.","0 Years","11 Years",{"count":243,"type":23},32,[200],"A study to evaluate the pharmacodynamic effects, safety, and tolerability of patiromer in children under 12 years of age with hyperkalaemia.",[247],"Hyperkalemia",{"date":225,"type":39},{"date":250,"type":39},"2025-04-06",{"date":252,"type":23},"2030-12-01",{"name":254,"class":130},"Vifor Pharma, Inc.",37,{"id":257,"slug":258,"hasResults":12,"nctId":259,"briefTitle":260,"officialTitle":261,"acronym":262,"eligibilityCriteria":263,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":264,"targetDuration":4,"studyType":90,"phases":4,"briefSummary":266,"conditions":267,"keywords":269,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":282,"locationsCount":243},"100540241","interstellar---international-study-evaluating-lupus-outcomes-after-anifrolumab-real-world-use-100540241","NCT06314282","INTERSTELLAR - International Study Evaluating Lupus Outcomes After Anifrolumab Real World Use","INTERSTELLAR - Multi-National, Observational, Prospective, Post-Launch, Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice","INTERSTELLAR","Inclusion Criteria:\n\n1. Aged 18 years or older at study enrolment.\n2. Fulfilled the 2019 EULAR\u002FACR criteria1 for SLE at the time of study entry.\n3. Prescribed anifrolumab for their SLE treatment for the first time, according to approved country-specific label.\n4. It is important to note that a physician decision to prescribe anifrolumab will need to occur prior to any study-related discussion.\n5. In countries where prescription reimbursements are authorized on a case-by-case basis, authorization (ie, patient access to treatment) will be required for study entry.\n6. Provided informed consent to participate in the study.\n7. Willing and able to participate in all required study evaluations and procedures.\n\nExclusion Criteria:\n\n1. Currently participating in an anifrolumab early access\u002Fcompassionate use program or an interventional clinical trial with an investigational product.\n2. Previous exposure to anifrolumab as part of a clinical trial or early access program.\n3. Documented diagnosis of severe or rapidly progressive Class III or IV glomerulonephritis requiring induction therapy (mycophenolate mofetil \\[MMF\\]\u002Fcyclophosphamide \\[CYC\\] + high dose steroids), isolated Class V lupus nephritis, or active severe or unstable neuropsychiatric lupus.\n4. Any other condition which the investigator deems to limit a patient's ability to understand the informed consent or complete the PROs.",{"count":265,"type":23},200,"INTERSTELLAR study will generate critical prospective real-world evidence on the benefits of adding Anifrolumab to standard of care treatment for SLE in routine clinical practice, to inform physicians, payers and patients. The study will use clinical assessments that are relevant for SLE-treating physicians in routine clinical practice, as well as introduce a specific measure for skin manifestations to affirm the potency of anifrolumab in treating SLE-related skin manifestations. The study will use standardized objectives, inclusion\u002Fexclusion criteria and outcome measures across all countries participating in this study including GCC (Qatar, KSA), Mexico, CAMCAR (Costa Rica, Panama, Dominican Republic), Colombia, Argentina, Taiwan, and Egypt, and any other countries that may be included in the study, in order to facilitate a comparison and analysis across all countries included in this study.",[268],"Systemic Lupus Erythematosus (SLE)",[270,271,272,273,274],"SLE","Systemic lupus erythematosus","autoimmune disease","Lupus","Anifrolumab","2026-07-16",{"date":277,"type":39},"2026-07-17",{"date":279,"type":39},"2024-10-22",{"date":281,"type":23},"2027-12-31",{"name":155,"class":130},{"id":284,"slug":285,"hasResults":12,"nctId":286,"briefTitle":287,"officialTitle":288,"acronym":4,"eligibilityCriteria":289,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":290,"targetDuration":195,"studyType":90,"phases":4,"briefSummary":292,"conditions":293,"keywords":295,"overallStatus":299,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":301,"startDateStruct":303,"completionDateStruct":305,"leadSponsor":307,"locationsCount":47},"100644973","qatar-cardiometabolic-cohort-100644973","NCT07675928","Qatar Cardiometabolic Cohort","Qatar Cardiometabolic Cohort (QCMC)","Inclusion Criteria:\n\n* Qataris\n* Long-term residents (≥15 years of residence in Doha) who are not planning to leave Qatar voluntarily within the next 5 years.\n* Age ≥18 years.\n* English or Arabic speaker.\n* Presence of either atherosclerotic cardiovascular disease (ASCVD) or very high cardiovascular risk.\n\n  1. ASCVD:\n\n     ASCVD is defined as either clinical ASCVD or unequivocally documented ASCVD on imaging, based on the European Society of Cardiology (ESC) guidelines for the management of cardiovascular disease in patients with diabetes.\n\n     i.Clinical ASCVD: History or presence of any of the following atherosclerotic events or revascularization in major arterial territories:\n     1. Coronary Artery Disease (CAD)\n\n        * Myocardial infarction (ST-elevation myocardial infarction (STEMI) or Non-ST-elevation myocardial infarction (NSTEMI))\n        * Stable or unstable angina with angiographic stenosis ≥50%\n        * History of coronary revascularization (Percutaneous coronary intervention (PCI) or Coronary artery bypass graft surgery (CABG))\n     2. Cerebrovascular Disease\n\n        * Ischemic stroke or transient ischemic attack (TIA)\n        * Symptomatic carotid artery stenosis ≥50% or prior carotid intervention\n     3. Peripheral Arterial Disease (PAD)\n\n        * Intermittent claudication with objective evidence of arterial obstruction\n        * Prior peripheral revascularization, limb amputation due to ischemia, or Ankle-brachial index ABI \\\u003C0.9\n     4. Aortic Atherosclerotic Disease •Aortic aneurysm (abdominal or thoracic) of atherosclerotic origin ii.Unequivocally Documented ASCVD on Imaging:\n\n     \u003C!-- -->\n\n     1. Coronary artery calcium (CAC) score \\>100 Agatston units or \\>75th percentile for age and sex\n     2. Coronary CT angiography or invasive angiography showing ≥50% stenosis in ≥1 major epicardial artery\n     3. Carotid ultrasound or angiography showing plaque or ≥50% stenosis\n     4. Lower-limb CT\u002FMR\u002FDoppler angiography showing atherosclerotic plaque or stenosis ≥50%\n  2. Very High Cardiovascular Risk i. In non-diabetic patients (ESC 2021 CVD Prevention Guidelines):\n\n     * 10-year fatal\u002Fnon-fatal ASCVD risk ≥10% using SCORE2 (ages 40-69), or ≥15% using SCORE2-OP (≥70 years)\n     * Severe chronic kidney disease (CKD) with estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73m² ii.In diabetic patients (ESC 2023 Diabetes \\& CVD Guidelines):\n     * 10-year cardiovascular risk ≥20% using SCORE2-Diabetes\n     * Severe target organ damage:\n\n  \u003C!-- -->\n\n  1. eGFR \\\u003C45 mL\u002Fmin\u002F1.73m² (regardless of albuminuria)\n  2. eGFR 45-59 mL\u002Fmin\u002F1.73m² with microalbuminuria (UACR 30-300 mg\u002Fg) or proteinuria (UACR \\>300 mg\u002Fg)\n  3. Microvascular disease in at least three sites (e.g., microalbuminuria, retinopathy, neuropathy)\n\nExclusion Criteria:\n\n* Type 1 diabetes or monogenic diabetes (e.g., MODY).\n* Pregnancy (self-reported).\n* Active cancer, under medical or radiation therapy or terminal, or cancer in remission \\\u003C 1 year.\n* Chronic immune or chronic infectious diseases.\n* End stage renal disease (ESRD) (estimated glomerular filtration rate \\\u003C15 mL\u002Fmin\u002F1.73m²).\n* Prisoners.\n* Inability or unwillingness to provide informed consent, including language barriers.\n* Mental incapacity.",{"count":291,"type":23},3000,"Our objective is to create a cardiometabolic cohort that could be representative of the local population, consisting of Qataris and long-term residents, in order to identify the prevalence, risk factors, and clinical characteristics of cardiometabolic disorders, as well as the incidence of atherosclerotic cardiovascular disease events.",[294],"Cardiometabolic Diseases",[296,297,298],"cardiometabolic diseases","atherosclerotic cardiovascular disease","diabetes","NOT_YET_RECRUITING","2026-06-23",{"date":302,"type":39},"2026-06-30",{"date":304,"type":23},"2026-06-01",{"date":306,"type":23},"2036-06-30",{"name":45,"class":46},{"id":309,"slug":310,"hasResults":12,"nctId":311,"briefTitle":312,"officialTitle":313,"acronym":314,"eligibilityCriteria":315,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":316,"targetDuration":4,"studyType":90,"phases":4,"briefSummary":318,"conditions":319,"keywords":322,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":323,"lastUpdatePostDateStruct":324,"startDateStruct":326,"completionDateStruct":328,"leadSponsor":330,"locationsCount":331},"100597965","a-multicenter-observational-study-to-understand-the-clinical-characteristics-treatment-patterns-and-access-to-novel-therapies-of-patients-with-diffuse-large-b-cell-lymphoma-in-the-mea-region-100597965","NCT07065344","A Multicenter Observational Study to Understand the Clinical Characteristics, Treatment Patterns and Access to Novel Therapies of Patients With Diffuse Large B-Cell Lymphoma in the MEA Region","A Multicenter Observational Study to Understand the Clinical Characteristics, Treatment Patterns and Access to Novel Therapies of Patients With Diffuse Large B-Cell Lymphoma in the MEA Region A Cross-sectional Multi-center, Observational Study to Describe the Disease Characteristics and Treatment Patterns and Explore Access to Novel Therapies for Diffuse Large B-Cell Lymphoma (DLBCL) Patients for Both Treatment naïve and Relapsed\u002FRefractory Patients in the Middle East & Africa (MEA) Region.","DOMAIN","Inclusion Criteria:\n\n1. Male or female patients aged 18 years or older at diagnosis.\n2. Patients who have confirmed diagnosis of diffuse large B-cell lymphoma (DLBCL) according to the investigator's decision and\u002For histopathological diagnosis.\n3. For Cohort 1: DLBCL patients who are eligible to start treatment\\* according to the investigator's decision.\n4. For Cohort 2: patients who are diagnosed with DLBCL and have failed at least one prior line of therapy.\n5. Patients willing to sign the written informed consent form (ICF) indicating that they understand the purpose of the study and procedures required for participation.\n\nExclusion Criteria:\n\n1. Patients who are not eligible for treatment for any reason, according to the investigator's judgment and decision\n2. Patients with concurrent active malignancies other than DLBCL.\n3. Patients who are actively participating in any other clinical trial.",{"count":317,"type":23},500,"Non-Hodgkin lymphoma (NHL) is the most common hematologic malignancy, with over 80,500 estimated new cases diagnosed in the United States in 20231. Diffuse large B-cell lymphoma (DLBCL) is the most frequent subtype of NHL, accounting for 30%-40% of cases2. DLBCL is an aggressive malignancy with heterogeneous biology and behavior. Disease risk stratification and treatment planning involve various patient and clinical characteristics (e.g., age, stage, and tumor bulk), prognostic indices (e.g., International Prognostic Index (IPI) score), and gene expression profiling. Patients typically present with nodal or extranodal disease, usually exhibiting rapid tumor growth and symptoms that are highly dependent upon the tumor localization.\n\nThe diagnosis and subtyping of DLBCL have significantly advanced, from morphological assessment of tissue slide to numerous ancillary tests, including immunophenotyping performed by immunohistochemistry (IHC), cytogenetics, and detailed molecular testing to classify the disease based on cell of origin (COO). With the advent of novel therapeutic options, molecular subtyping of DLBCL at diagnosis is expected to allow prognostic stratification of patients into distinct subgroups. This stratification could provide a preclinical rationale for therapeutic targeting the involved pathways and paving the application of personalized treatment.\n\nDLBCL is a potentially curable disease with an overall 60-70% chance of achieving durable complete remission (CR) with the currently used standard first-line immunochemotherapy. However, 30-40% of patients are either refractory to first-line treatment or experience relapse and eventually will die of disease progression7. Although high-dose chemotherapy followed by autologous stem cell transplant (ASCT) is the recommended SOC for eligible patients in the second-line setting based on results from the pivotal PARMA study, real-world SOC in this setting remains less clearly defined.\n\nPatients not cured with ASCT or ineligible to ASCT or refractory to salvage chemotherapy may be considered for Chimeric Antigen Receptor (CAR) T cell therapy targeting CD1910. Although ASCT and CAR-T cell therapy offer patients an opportunity for durable remission, many patients may not be eligible for ASCT or CAR-T cell therapy or relapse after these treatments. In the last decade, the investigation of novel antigens, which can be targeted by immunotherapy and identified to eliminate malignant cells regardless of their molecular pathogenesis, has been constantly pursued.\n\nThis study aims to address this need by examining the demographic, clinical characteristics, and treatment patterns and exploring access to novel therapies for diffuse large B-cell lymphoma (DLBCL) patients, both treatment naïve and relapsed\u002Frefractory patients, in the Middle East and Africa (MEA) region.",[320,321],"Hematology","Diffused Large B Cell Lymphoma",[321],"2026-06-17",{"date":325,"type":39},"2026-06-18",{"date":327,"type":39},"2025-07-23",{"date":329,"type":23},"2027-01-31",{"name":155,"class":130},21,{"id":333,"slug":334,"hasResults":12,"nctId":335,"briefTitle":336,"officialTitle":337,"acronym":338,"eligibilityCriteria":339,"healthyVolunteers":12,"sex":18,"minAge":340,"maxAge":341,"enrollmentInfo":342,"targetDuration":4,"studyType":24,"phases":344,"briefSummary":345,"conditions":346,"keywords":348,"overallStatus":299,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":353,"startDateStruct":355,"completionDateStruct":357,"leadSponsor":359,"locationsCount":47},"100640565","phase-3-metformin-treatment-for-children-with-obesity-associated-asthma-100640565","NCT07622290","Metformin Treatment for Children With Obesity-associated Asthma","The Role of Metformin in Asthma Control in Obese\u002FOverweight Children, a Randomized Placebo Controlled Clinical Trial","MOACT","Inclusion Criteria:\n\n* Participant who are capable of giving assent and parentral consent\n* Male\u002FFemale participant aged between10-17 years old,\n* overweight\u002Fobese children (Overweight and obesity are defined as BMI equal and above the 85th percentile, and BMI above the 95th percentile for age and sex, respectively).\n* Diagnosed with mild persistent, moderate persistent \u002Fsevere asthma based on GINA guidelines within the 6 months prior to the recruitment date and having ACT score \\\u003C 20, residing in Qatar\n* Partcipants on standard asthma therapy for at least the last 6 months prior to the recruitment\n* Participant who are currently not taking part in any other interventional study\n\nExclusion Criteria:\n\n* Non-asthma chronic lung disease\n* Broncho-pulmonary dysplasia\n* Inflammatory bowel disease\n* Syndromic disorders (e.g. Down's syndrome, Turner's syndrome)\n* Inborn errors of metabolism\n* Symptomatic or previously symptomatic congenital heart disease\n* Craniofacial abnormalities\n* Primary thoracic cage abnormalities\n* Neuromuscular disorders\n* Swallowing disorders\n* Secondary endocrinopathies causing obesity\n* Renal complications\n* Ongoing treatment for cancer\n* Taking metformin or GLP1 medication less than 3 months of the recruitment date\n* Children diagnosed with type-1 diabetes","10 Years","17 Years",{"count":343,"type":23},182,[170],"The goal of this clinical trial is to learn if metformin can improve asthma control in overweight and obese children with mild, moderate, or severe asthma. It will also evaluate the safety and metabolic effects of metformin in this population. The main questions the study aims to answer are:\n\n1\\) Does metformin improve asthma control, as measured by the Asthma Control Test (ACT) score? 2) Does metformin improve lung function, reduce asthma exacerbations, and improve metabolic and inflammatory markers in overweight\u002Fobese children with asthma? Researchers will compare metformin with a placebo (a look-alike substance that contains no active drug) to see if metformin improves asthma outcomes in overweight\u002Fobese children with asthma. Participants will take either metformin or a placebo in addition to their standard asthma treatment during the study period. They will attend scheduled clinic visits for asthma assessments, lung function testing, and safety monitoring. Blood, stool, and saliva samples, along with clinical information, will be collected from participants to assess asthma control, and markers related to metabolism and inflammation. Participants will also complete asthma control questionnaires and report medication use and asthma symptoms throughout the study period.",[347],"Obesity-associated Asthma",[349,350,351],"obesity-associated asthma","pediatric asthma","metformin","2026-05-30",{"date":354,"type":39},"2026-06-03",{"date":356,"type":23},"2026-06",{"date":358,"type":23},"2028-03",{"name":360,"class":46},"Prof Ibrahim Janahi",{"id":362,"slug":363,"hasResults":12,"nctId":364,"briefTitle":365,"officialTitle":366,"acronym":367,"eligibilityCriteria":368,"healthyVolunteers":12,"sex":18,"minAge":369,"maxAge":370,"enrollmentInfo":371,"targetDuration":4,"studyType":24,"phases":373,"briefSummary":374,"conditions":375,"keywords":377,"overallStatus":299,"whyStopped":4,"lastUpdateSubmitDate":381,"lastUpdatePostDateStruct":382,"startDateStruct":384,"completionDateStruct":385,"leadSponsor":387,"locationsCount":389},"100638609","phase-3-alirocumab-for-stabilisation-of-symptomatic-vulnerable-carotid-plaque-100638609","NCT07586540","Alirocumab for Stabilisation of Symptomatic Vulnerable Carotid Plaque","Alirocumab for Stabilisation of Symptomatic Vulnerable Carotid Plaque: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Trial With High-Resolution Vessel-Wall MRI and Clinical Endpoints","CAROTID-STABIL","Inclusion Criteria:\n\n1. Age ≥ 40 and ≤ 80 years\n2. Recently symptomatic (TIA, amaurosis fugax, or non-disabling ischaemic stroke with mRS ≤ 2) referable to a carotid territory within 28 days of randomisation\n3. Ipsilateral extracranial internal carotid artery stenosis of 50-69% by NASCET criteria on CTA or DSA\n4. HR-VW-MRI evidence of IPH (MPRAGE hyperintensity ≥150% of adjacent sternocleidomastoid) OR LRNC ≥ 10% of plaque volume in the symptomatic plaque\n5. On a stable dose of high-intensity statin (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) for ≥ 4 weeks, or able and willing to initiate atorvastatin 80 mg daily at randomisation\n6. LDL-C ≥ 70 mg\u002FdL (1.8 mmol\u002FL) at screening\n7. Able to undergo 3T MRI (no contraindications)\n8. Provides written informed consent\n\nExclusion Criteria:\n\n1. Indication for urgent carotid revascularisation within 14 days per treating team\n2. Disabling stroke (mRS \\> 2) or NIHSS \\> 5 at randomisation\n3. Carotid stenosis ≥ 70% or occlusion\n4. Cardioembolic stroke source (atrial fibrillation, LV thrombus, endocarditis, PFO with high-risk features)\n5. Intracranial haemorrhage within 12 months or any history of symptomatic ICH\n6. eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²\n7. Active hepatobiliary disease or ALT\u002FAST \\> 3x ULN\n8. Prior exposure to any PCSK9 inhibitor or inclisiran within 6 months\n9. Known hypersensitivity to alirocumab or excipients\n10. Pregnancy, breastfeeding, or unwillingness to use contraception in women of childbearing potential\n11. Life expectancy \\\u003C 24 months\n12. Participation in another interventional trial within 30 days\n13. Inability to comply with follow-up or MRI schedule","40 Years","80 Years",{"count":372,"type":23},280,[170],"CAROTID-STABILISE is a phase III, multicentre, randomised, double-blind, placebo-controlled trial evaluating whether alirocumab 150 mg subcutaneously every 2 weeks, added to high-intensity statin therapy, produces greater reduction in intraplaque haemorrhage (IPH) volume at 26 weeks compared with placebo in patients with recently symptomatic carotid stenosis of 50-69% harbouring IPH or lipid-rich necrotic core (LRNC) on high-resolution vessel-wall MRI. The study will enroll 280 participants across multiple centres with a 52-week extension for durability and clinical endpoints assessment.",[376],"Carotid Stenosis",[378,379,380],"vulnerable plaque","alirocumab","PCSK9 inhibitor","2026-05-08",{"date":383,"type":39},"2026-05-14",{"date":207,"type":23},{"date":386,"type":23},"2030-09",{"name":388,"class":46},"Middle East North Africa Stroke and Interventional Neurotherapies Organization",14,{"id":391,"slug":392,"hasResults":12,"nctId":393,"briefTitle":394,"officialTitle":394,"acronym":4,"eligibilityCriteria":395,"healthyVolunteers":55,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":396,"targetDuration":398,"studyType":90,"phases":4,"briefSummary":399,"conditions":400,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":403,"lastUpdatePostDateStruct":404,"startDateStruct":406,"completionDateStruct":408,"leadSponsor":410,"locationsCount":47},"100635731","role-of-endothelial-progenitor-cells-dysregulation-and-inflammation-in-the-pathophysiology-of-cardiovascular-complications-of-type-2-diabetes-100635731","NCT07556497","Role of Endothelial Progenitor Cells Dysregulation and Inflammation in the Pathophysiology of Cardiovascular Complications of Type 2 Diabetes","Inclusion Criteria:\n\n* T2D\n* Males and females\n* Older than 18 years of age\n* Willingness to participate in the study and provide written consent form\n* Consent to having peripheral blood withdrawals and urine collection for the study requirement.\n\nExclusion Criteria:\n\n* Unable to meet the inclusion criteria\n* Type I diabetes, MODY diabetes or other form of diabetes\n* Active infection, inflammation, cancer or acute illness of any kind (other than a cardiovascular complication of diabetes if applicable in the group they are assigned to).\n* Chronic inflammation (eg. auto-immune diseases) or infections (eg. HIV, chronic hepatitis).\n* Evidence of malignancy within the past 5 years",{"count":397,"type":23},90,"6 Months","This study aims to isolate endothelial progenitor cells (EPCs) from participants with type 2 diabetes (T2D) and cardiovascular complications and to comprehensively characterize EPC dysfunction. Specifically, the study will evaluate maladaptive angiocrine signaling, calcium signaling pathways, and the role of inflammation in EPC function and the progression of atherosclerosis during T2D development. A sub-study will assess EPC functionality by examining endothelial nitric oxide synthase (eNOS) expression and activity, as well as the effectiveness of in vitro eNOS gene enhancement.",[401,402],"Diabete Type 2","Cardio Vascular Disease","2026-04-21",{"date":405,"type":39},"2026-04-29",{"date":407,"type":39},"2020-11-17",{"date":409,"type":23},"2026-12-31",{"name":45,"class":46},{"id":412,"slug":413,"hasResults":12,"nctId":414,"briefTitle":415,"officialTitle":416,"acronym":417,"eligibilityCriteria":418,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":166,"enrollmentInfo":419,"targetDuration":4,"studyType":24,"phases":421,"briefSummary":422,"conditions":423,"keywords":425,"overallStatus":299,"whyStopped":4,"lastUpdateSubmitDate":429,"lastUpdatePostDateStruct":430,"startDateStruct":432,"completionDateStruct":434,"leadSponsor":436,"locationsCount":389},"100635104","mena-regional-endovascular-intervention-for-venous-cerebral-venous-sinus-thrombosis-100635104","NCT07548346","MENA Regional Endovascular Intervention for Venous Cerebral Venous Sinus Thrombosis","REVIVE-CVST: A Multicenter, Prospective, Randomized, Open-Label, Blinded-Endpoint (PROBE) Trial of Endovascular Thrombectomy Plus Standard Medical Care Versus Standard Medical Care Alone in Adults With Acute or Subacute Cerebral Venous Sinus Thrombosis at High Risk of Poor Outcome in the Middle East and North Africa Region","REVIVE-CVST","Inclusion Criteria:\n\n* Age 18-65 years, inclusive\n* Radiologically confirmed cerebral venous sinus thrombosis (CVST) by CT venography (CTV), MR venography (MRV), or digital subtraction angiography (DSA), with thrombosis of at least one major dural sinus\n* Acute or subacute presentation with symptom onset within 21 days of randomization\n* MRI phase characterization confirming acute or subacute phase\n* At least one risk factor for poor outcome: symptoms of intracranial hypertension (severe headache, papilledema, visual obscurations), focal neurological deficit, seizures, altered consciousness (GCS 9-14), intracranial hemorrhage from venous congestion, or deep venous system thrombosis\n* Significant venous outflow obstruction on imaging\n* Written informed consent from patient or legally authorized representative\n\nExclusion Criteria:\n\n* Isolated cortical vein thrombosis without dural sinus involvement\n* Isolated cavernous sinus thrombosis\n* Chronic-phase CVST on MRI phase characterization\n* Pre-morbid modified Rankin Scale (mRS) score greater than 2\n* Glasgow Coma Scale (GCS) score less than 9 at randomization\n* Imminent risk of transtentorial herniation requiring emergent decompressive craniectomy\n* Massive cerebral edema with midline shift greater than 10 mm requiring surgical intervention\n* Active systemic bleeding or hemorrhagic diathesis\n* Severe allergy to iodinated contrast media\n* CVST secondary to active hematological malignancy or life expectancy less than 12 months\n* Pregnancy\n* Participation in another interventional clinical trial within 30 days\n* Any condition rendering the patient unsuitable for study participation per investigator judgment",{"count":420,"type":23},440,[26],"REVIVE-CVST is a multicenter, prospective, randomized, open-label, blinded-endpoint (PROBE) trial evaluating whether early endovascular thrombectomy (EVT) combined with standard anticoagulation improves outcomes compared to anticoagulation alone in patients with severe cerebral venous sinus thrombosis (CVST).\n\nThe study targets adult patients (aged 18 years or older) presenting within 14 days of symptom onset with imaging-confirmed CVST and at least one severity marker, such as a Glasgow Coma Scale score of 14 or below, intracerebral hemorrhage, venous infarction, or deep venous system involvement.\n\nParticipants will be randomly assigned in a 1:1 ratio to either the intervention arm (EVT plus anticoagulation) or the control arm (anticoagulation alone). The primary endpoint is functional outcome at 180 days as measured by the modified Rankin Scale (mRS), using a shift analysis across all mRS categories.\n\nThe trial aims to enroll 440 participants across approximately 15 centers in the Middle East, North Africa, South Asia, and Turkey (MENA-SINO network). The study duration is approximately 42 months, including 18 months of enrollment and 12 months of follow-up for the last enrolled patient.",[424],"Cerebral Venous Sinus Thrombosis",[426,427,428],"CVST","endovascular thrombectomy","anticoagulation","2026-04-16",{"date":431,"type":39},"2026-04-23",{"date":433,"type":23},"2026-07",{"date":435,"type":23},"2030-01",{"name":388,"class":46},{"id":438,"slug":439,"hasResults":12,"nctId":440,"briefTitle":441,"officialTitle":441,"acronym":442,"eligibilityCriteria":443,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":444,"targetDuration":446,"studyType":90,"phases":4,"briefSummary":447,"conditions":448,"keywords":4,"overallStatus":299,"whyStopped":4,"lastUpdateSubmitDate":453,"lastUpdatePostDateStruct":454,"startDateStruct":455,"completionDateStruct":456,"leadSponsor":458,"locationsCount":47},"100632601","qatar-cardiometabolic-retrospective-cohort-analysis-using-artificial-intelligence-100632601","NCT07515807","Qatar Cardiometabolic Retrospective Cohort-Analysis Using Artificial Intelligence","QCRC-AI","Inclusion Criteria:\n\n* Age ≥ 18\n* Qatari and Arab participants\n* Participants admitted for Acute Coronary Syndrome (ACS) or Acute Heart Failure (AHF)\n* Metabolic disease: Diabetes (HbA1C ≥ 6.5% or any HbA1C if a patient is on an antidiabetic agent) or pre-diabetes: 5.7% ≤ HbA1c ≤ 6.4%\n\nExclusion Criteria:\n\n* Non-Qatari or non-Arab participants\n* Non-diabetic: HbA1C \\\u003C 5.7%\n* This chart review involves no direct interaction with individuals. Prisoners are not a focus of this study, and incarceration status is not identifiable in the records reviewed.",{"count":445,"type":23},10000,"2 Years","Cardiovascular disease is the leading cause of death worldwide, and individuals with diabetes or other cardiometabolic conditions are at increased risk of adverse cardiovascular outcomes. Although advances in prevention and treatment have reduced cardiovascular events globally, cardiometabolic disease continues to represent a significant health burden, particularly in regions with high diabetes prevalence. In Qatar and other Gulf Cooperation Council countries, the prevalence of diabetes and obesity is increasing, contributing to a high proportion of participants presenting with acute coronary syndrome who have type 2 diabetes or prediabetes. This observational study will use electronic medical record data from patients hospitalized at the Heart Hospital with acute coronary syndrome and a concomitant diagnosis of diabetes or prediabetes. The study will assess trends in cardiovascular risk factors and cardiovascular events, including readmission and mortality. An artificial intelligence component will be used to develop and validate machine learning based risk prediction models to forecast adverse cardiovascular outcomes in participants with cardiometabolic disease. These models will integrate clinical, biochemical, imaging, and other non-invasive data routinely collected during participants care to identify predictors of cardiovascular events.",[402,449,450,451,452],"Acute Coronary Syndromes (ACS)","Type 2 Diabetes","Pre Diabetes","Artifical Intelligence","2026-04-15",{"date":403,"type":39},{"date":275,"type":23},{"date":457,"type":23},"2030-07-16",{"name":45,"class":46},{"id":460,"slug":461,"hasResults":12,"nctId":462,"briefTitle":463,"officialTitle":464,"acronym":465,"eligibilityCriteria":466,"healthyVolunteers":12,"sex":18,"minAge":467,"maxAge":468,"enrollmentInfo":469,"targetDuration":4,"studyType":24,"phases":471,"briefSummary":472,"conditions":473,"keywords":475,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":477,"lastUpdatePostDateStruct":478,"startDateStruct":480,"completionDateStruct":482,"leadSponsor":484,"locationsCount":47},"100632499","lisa-vs-endotracheal-surfactant-in-preterm-neonates-a-lung-ultrasound-distribution-study-100632499","NCT07514481","LISA vs Endotracheal Surfactant in Preterm Neonates: A Lung Ultrasound Distribution Study","A Prospective Pilot Controlled Trial Comparing the Intrapulmonary Distribution of Exogenous Surfactant Between (LISA) and Conventional Endotracheal Intubation in Preterm Neonates With RDS Using Lung Ultrasound and the NOVEL Surfactant Distribution Homogeneity Index (SDHI)","LISA-Ven-LUS","Inclusion Criteria:\n\nGestational age 24+0 to 42+6 weeks. Clinical and radiographic diagnosis of Respiratory Distress Syndrome (RDS). Requirement for surfactant within the first 3 days of life. Written informed parental consent.\n\nExclusion Criteria:\n\nInfants intubated at birth or who received surfactant prophylactically in the delivery room.\n\nMajor congenital anomalies or lung malformations (e.g., congenital diaphragmatic hernia, pulmonary hypoplasia).\n\nSyndromic or genetic conditions affecting lung or chest wall development. Severe hemodynamic instability or congenital heart disease requiring intensive support.\n\nLack of parental consent for trial participation.","24 Weeks","42 Weeks",{"count":470,"type":23},22,[26],"This prospective, non-randomized, unblinded pilot study evaluates and compares the intrapulmonary distribution of exogenous surfactant in preterm neonates when administered via Less Invasive Surfactant Administration (LISA) versus conventional endotracheal intubation (ETT). Lung ultrasound (LUS) will be utilized to assess the pioneer Surfactant Distribution Homogeneity Index (SDHI) to quantify the evenness and extent of surfactant-induced lung aeration. Secondary objectives include evaluating changes in LUS scores, short-term clinical respiratory outcomes, and feasibility parameters for guiding future larger-scale trials.",[474],"Respiratory Distress Syndrome, Newborn",[476],"Less Invasive Surfactant Administration, LISA, Lung Ultrasound, Neonatology, Surfactant Distribution Homogeneity Index","2026-04-01",{"date":479,"type":39},"2026-04-07",{"date":481,"type":39},"2026-01-01",{"date":483,"type":23},"2026-07-30",{"name":485,"class":486},"Hamad General Hospital","OTHER_GOV",{"id":488,"slug":489,"hasResults":12,"nctId":490,"briefTitle":491,"officialTitle":492,"acronym":493,"eligibilityCriteria":494,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":495,"targetDuration":4,"studyType":24,"phases":497,"briefSummary":498,"conditions":499,"keywords":501,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":505,"lastUpdatePostDateStruct":506,"startDateStruct":508,"completionDateStruct":509,"leadSponsor":511,"locationsCount":47},"100616791","pharmacist-led-transition-of-care-program-in-the-emergency-department-pharm-toc-ed-a-pilot-trial-100616791","NCT07310199","Pharmacist-Led Transition of Care Program in the Emergency Department (Pharm TOC-ED): A Pilot Trial","Pharmacist-Led Transition of Care Program in the Emergency Department (Pharm TOC-ED): A Pilot Randomized, Parallel-Group, Open-Label Trial With Embedded Process Evaluation","PharmTOC-ED","Inclusion Criteria:\n\n* Adults (aged 18 years or more) discharged from the ED with at least one of the following:\n* Polypharmacy: Five or more scheduled prescription medications for chronic illnesses (i.e., chronic maintenance medications, even if such medications were not refilled during the index ED visit)\n* Discharged with a new prescription of high-risk medication, including:\n* Drugs with the potential of withdrawal symptoms upon abrupt discontinuation such as antipsychotics, antiepileptics, antidepressants, and tapering glucocorticoids.\n* Insulin (initiation or intensification of therapy)\n* Oral hypoglycemic agents\n* Visiting ED for an exacerbation of chronic illness (e.g., exacerbation of asthma, COPD, CHF, uncontrolled diabetes mellitus, hypertension urgency, uncontrolled epilepsy)\n\nExclusion Criteria:\n\n* The following patients will be excluded:\n* Presenting with acute minor illnesses\n* Lack of decision-making capacity (including documented moderate or severe dementia, altered mental status, unstable psychiatric illness, altered consciousness level, lack of orientation to person\u002Fplace\u002Ftime as reported in EHR, delirium, patients seen in the ED for a psychiatric evaluation)\n* Language barrier, i.e., inability to communicate in either English or Arabic as the intervention will be provided by English\u002FArabic speaking clinical pharmacists\n* Expected length of stay in Qatar of \\\u003C30 days post discharge (including transit passengers)\n* Substance use disorders (e.g., alcoholism, opioid dependency) or drug-seeking behavior, as reported in EHR\n* Prisoners who are serving an active sentence\n* Patients presenting for non-medical, socially driven reasons (e.g., seeking shelter, support, or resources) with no identifiable acute medical condition, and known to the ED team as recurrent visitors.\n* Discharge to a location other than home (e.g., patients transferred to another hospital, long-term or skilled nursing facility)\n* Study pharmacists unavailable to deliver the intervention if the patients were randomized to the intervention arm\n* Pregnant women\n* Patients seen for trauma or planned surgery\n* Terminally ill patients\n* Patients discharged from ED with watchful waiting (e.g., expected to be readmitted for an intervention such as surgical intervention if conservative management failed)\n* Patients who are admitted to the hospital after enrollment (i.e., following consent but prior to ED discharge)",{"count":496,"type":23},82,[26],"When patients leave the emergency department, mistakes with their medications are common and can lead to complications or hospital readmissions. Pharmacists are trained to help prevent these problems, but pharmacist-led transition of care services are not routinely provided in emergency departments.\n\nThis study is a small pilot randomized controlled trial designed to see whether a pharmacist-led transition of care program can be carried out successfully in the emergency department at Al-Wakra Hospital. The study will help determine if a larger trial is feasible in the future.\n\nPatients who are being discharged home from the emergency department and meet the study criteria will be invited to participate. Those who agree will be randomly assigned to one of two groups:\n\nUsual care, or Usual care plus the pharmacist-led transition of care program The pharmacist-led program includes reviewing the discharge prescription, checking and updating the medication list, providing medication education, arranging follow-up with a pharmacist-run clinic, communicating with outpatient pharmacists, and following up with the patient after discharge.\n\nThe pilot trial will help determine how many patients are eligible, how many agree to participate, how well the intervention can be delivered in the emergency department, and whether patients and staff find it acceptable. The results will be used to plan a larger study that will test whether this program can reduce healthcare use after discharge.",[500],"Transitional Care",[502,503,504],"transition of care","Pharmacy services","Emergency Department","2026-01-19",{"date":507,"type":39},"2026-01-21",{"date":505,"type":39},{"date":510,"type":23},"2027-04-10",{"name":512,"class":46},"Dr. Muhammad Abdul Hadi",{"id":514,"slug":515,"hasResults":12,"nctId":516,"briefTitle":517,"officialTitle":518,"acronym":4,"eligibilityCriteria":519,"healthyVolunteers":12,"sex":140,"minAge":19,"maxAge":166,"enrollmentInfo":520,"targetDuration":4,"studyType":24,"phases":521,"briefSummary":522,"conditions":523,"keywords":529,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":535,"lastUpdatePostDateStruct":536,"startDateStruct":538,"completionDateStruct":540,"leadSponsor":542,"locationsCount":47},"100619994","effects-of-pemm-in-chronic-low-back-pain-women-with-urinary-incontinence-100619994","NCT07351851","Effects of PEMM in Chronic Low Back Pain Women With Urinary Incontinence","Effects of PEMM in Chronic Low Back Pain Women With Urinary Incontinence A Randomised Controlled Trial","Inclusion Criteria:\n\n* Age group of 18 - 65 years\n* Has child\u002Fchildren \\\u003C5 parity\n* CLBP patients with UI referred for physiotherapy for CLBP\n* Patient with low back pain for more than 3 months\n* NRS more than 5\u002F10\n* Patient with complain of urinary incontinence since past 3 months or more\n\nExclusion Criteria:\n\n* Chronic Low Back Pain with red flags\n* Not able to read and write in English \u002FArabic\n* Pregnant ladies and post partum 1 year\n* UTI, Pelvic floor Surgery\n* Any systemic condition of renal and cardiac\n* Patient with active carcinoma or any inflammatory disease",{"count":265,"type":23},[26],"Urinary incontinence (UI), Chronic low back pain (CLBP) in women are prevalent and often coexist. Multiple conditions when coexist, it leads to reduced Quality of life in turn causing physical and mental impairment. Musculoskeletal structures and fascial restrictions is one of the attribute to the coexistence of urinary incontinence and chronic back pain in women. External myofascial mobilization (EMM) with core exercises have been proven beneficial for conditions in males that is caused by musculoskeletal and fascial structures. However there are limited research which proves the effect of EMM in conditions involving musculoskeletal and fascial structures . Therefore, the aim of the study is to find the effect of MFTs in reducing the disability in women with CLBP and UI PRIMARY OBJECTIVE To evaluate the effectiveness of PEMM treatment in reducing disability, pain and improving mental health in women with CLBP and UI Study design : Simple randomization Sampling method: Simple Random sampling Random numbers will be generated in Excel, then random numbers will be presented in a concealed envelope for the participants to choose Sample Size : 130 (Experimental 65, Control 65) Sample size was determined using expected effect size i.e., mean change in the primary outcome variable disability index reported in the recent research study . With effect size (change in the disability index score) 3.5 and standard deviation of the change in the outcome 6.45, statistical power 80% and level of significance 5%, the required sample size would be n=55 participants in each group. However, to accounts for multiple secondary outcome measures, possible dropouts and non-response it would be good to increase an additional 20% in calculated sample size i.e., a total of 130 participants (65 participants in each group) will be included in this study.\n\nThe following sample size equation was used to determine adequate sample size:n = \\[2 (Z?\u002F2 + Z?)2 \\* ?2\\] \u002F (m1-m2)2 Where Z? and Z? are the values standard normal variate e.g., at 5% level of significance Z?\u002F2 = 1.96, and with 80% power the value of Z?= 0.84; ? is the polled Standard deviation and m1 and m2 are the mean outcome values s in group 1 and group 2 respectively.\n\nBlinding:\n\nSingle blinding: patient will be blinded to the group allocation. The assessor is blinded to the treatment\n\nMaterial and tools :\n\nTheragun - Theragun Elite, 20 V, Myofascial tools - foam roll, foam ball, Questionnaires - SF 3642,43,44, Oswestry Low back pain questionnaire (ODI)45 and The International Consultation on Incontinence Questionnaire Urinary Incontinence Short Form (ICIQ-UI-SF)46 PROCEDURE In the course of the study the total number of patients referred to physiotherapy department with LBP will be interviewed to identify patients with or without UI having LBP. The data obtained from this will be recoded as prevalence in results. The documents of the patients having LBP with UI will be reviewed to check who fulfills the inclusion criteria. All who meets the inclusion criteria will be approached face to face with the aim of the study. Informed consent form will be given to patients who are volunteering to participate in the study. The data of the participants who do not wish to participate in the study will also be recorded.\n\nThe participants who have consented to participate in the study will be then assessed. Since the participants has UI she will be directed to a Urologist for an assessment. After urologist assessment, patients will be randomly allocated to experimental and control groups. Random allocation will be administered by the random numbers generated and will be presented in a concealed envelope for the participants to choose. 1st week, the demographic data and Outcome measure of pain, SF36, ODI, ICIQ-UI-SF will be recorded (1st time) on the day of assessment. The outcome measures will be printed on paper and will be given to the patients to fill up with a pen, all questionnaires are self reported outcome measures. Treatment will commence a week after, where experimental group will undergo PEMM therapy with strengthening for 6 weeks duration and the control group will have conventional symptomatic pain treatment with strengthening (2nd to 7th week). Treatment will be given for 6 weeks (1 sessions in a week). The treatment day may vary any day between 4th and 7th day post one session. After 6 sessions of treatment, patient will be advised HEP (Home exercise program) to continue at home. Reassessment will be done on the 8th week where the outcome measures of pain, SF36, ODI, ICIQ-UI-SF will be recorded. Participants will be educated and advised regarding HEP. Exercises will be taught to the patient by explanation, demonstration, teach-back method, and printed sheet of exercise. Compliance to HEP will be recorded before final Outcome measure",[524,525,526,527,528],"Chronic Low-back Pain (cLBP)","Urinary Incontinence (UI)","Pelvic External Myofascial Mobilisation","Myofascial Techniques","Pelvic Pain",[530,531,532,533,534],"chronic low back pain","urinary incontinence","myofascial mobilisation","PEMM","female pelvic pain","2026-01-11",{"date":537,"type":39},"2026-01-20",{"date":539,"type":39},"2025-09-29",{"date":541,"type":23},"2027-12",{"name":543,"class":130},"Hamad Medical Corporation",{"id":545,"slug":546,"hasResults":12,"nctId":547,"briefTitle":548,"officialTitle":549,"acronym":550,"eligibilityCriteria":551,"healthyVolunteers":12,"sex":140,"minAge":552,"maxAge":553,"enrollmentInfo":554,"targetDuration":4,"studyType":24,"phases":556,"briefSummary":557,"conditions":558,"keywords":560,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":568,"lastUpdatePostDateStruct":569,"startDateStruct":571,"completionDateStruct":572,"leadSponsor":573,"locationsCount":47},"100618560","scheduled-positioning-with-a-peanutballspp-on-labor-outcomes-among-primiparous-women-under-epidural-analgesia-100618560","NCT07333209","Scheduled Positioning With a Peanutball(SPP) on Labor Outcomes Among Primiparous Women Under Epidural Analgesia","Determine the Impact of Scheduled Positioning With a Peanutball on Labor Outcomes Among Primiparous Women Under Epidural Analgesia: A Non-Invasive Randomized Controlled Trial","Peanutball","Inclusion Criteria:Inclusion Criteria:\n\nTo be eligible for participation, women must meet all the following criteria:\n\n* Primiparous (first pregnancy resulting in a live birth or stillbirth after 20 weeks of gestation).\n* Singleton at gestation.\n* Gestational age of the term (37 weeks 0 days to 41 weeks 6 days).\n* Admitted to the Labor and Delivery Unit at WWRC in active labor.\n* Received epidural analgesia for labor pain management.\n* Expected to have a vaginal delivery (e.g., no contraindications for vaginal birth identified at the time of recruitment).\n* Able to understand and communicate in Arabic or English.\n* Provide written informed consent.\n\nExclusion Criteria:The birthing ball should NOT be used in any of the following conditions:\n\n1. Obstetric Contraindications (Maternal)\n\n   * Any situation where vaginal birth is not appropriate (e.g., absolute indication for cesarean section)\n   * Non-progress of labor requiring immediate intervention\n   * Severe pre-eclampsia\u002Feclampsia\n   * Active vaginal bleeding of unknown cause\n   * Placenta previa (major) or vasa previa\n   * Placental abruption (suspected or confirmed)\n   * Preterm labor with medical contraindication to ambulation or mobility\n   * Ruptured membranes with unstable fetal head (high station) → Risk of cord prolapse\n   * Severe maternal exhaustion requiring bed rest\n   * Maternal hemodynamic instability\n2. Fetal Contraindications\n\n   * Non-reassuring fetal heart rate requiring continuous monitoring (Category II-III tracings)\n   * Malpresentation requiring immediate obstetric intervention (e.g., transverse lie)\n   * Suspected macrosomia with mechanical obstruction concerns (e.g., cephalopelvic disproportion)\n   * Multiple gestation with instability or complications\n3. Orthopedic \u002F Musculoskeletal Contraindications\n\n   * Any condition that prevents safe sitting, balancing, or weight-bearing, such as: Severe hips, leg, knee, or pelvic injuries\n   * Significant arthritis of the lower limbs or pelvis\n   * Recent joint surgery (hip\u002Fknee replacement, pelvic repair)\n   * Neuromuscular disorders affecting balance (e.g., severe neuropathy)\n   * Severe sciatica limiting mobility\n   * Poor trunk control or inability to maintain safe seated posture\n4. High-Risk Pregnancy Conditions\n\n   * Use of birthing balls is contraindicated if pregnancy is classified as high-risk, including Uncontrolled gestational diabetes and Uncontrolled hypertension\n   * Intrauterine growth restriction with required continuous monitoring\n   * Polyhydramnios or severe oligohydramnios (risk of cord compression\u002Finstability)\n   * Preterm premature rupture of membranes (PPROM)\n   * History of preterm birth with current instability\n   * Any condition requiring bed rest or reduced mobility\n5. Safety \u002F Environmental Contraindications\n\n   * Patients are unable to follow instructions or unsteady balance\n   * No trained staff available to supervise during labor use Unstable or improperly sized birthing ball","16 Years","55 Years",{"count":555,"type":23},110,[26],"Brief Summary\n\nThe goal of this clinical trial is to evaluate whether scheduled maternal position changes using a peanut birthing ball improve labor outcomes in low-risk, primiparous women receiving epidural analgesia during labor. The main questions it aims to answer are:\n\nDoes scheduled maternal positioning with a peanut ball reduce the duration of the first and second stages of labor?\n\nDoes scheduled maternal positioning with a peanut ball influence mode of delivery and maternal and neonatal outcomes?\n\nThis non-invasive randomized controlled trial will be conducted at the Women's Wellness and Research Center in Qatar. Participants will be randomly assigned to either an intervention group receiving scheduled maternal position changes using a peanut birthing ball or a control group receiving standard intrapartum care without peanut ball use. Researchers will compare outcomes between the two groups to determine whether structured positioning with a peanut ball improves labor progression and delivery outcomes in women receiving epidural analgesia.\n\nParticipants in the intervention group will undergo scheduled position changes throughout labor using a peanut birthing ball, including left lateral, right lateral, semi-sitting, and Taylor positions, under the supervision of trained nursing and midwifery staff. Participants in the control group will receive routine intrapartum care following epidural analgesia without the use of a peanut ball or a structured positioning schedule.\n\nPrimary maternal outcomes include duration of the first and second stages of labor, mode of delivery, estimated blood loss, postpartum hemorrhage, use of oxytocin augmentation, degree of perineal trauma, and hospitalization cost. Neonatal outcomes include Apgar scores at 5 and 10 minutes, NICU admission, birth-related injuries, and umbilical cord blood pH. Findings from this study are expected to support evidence-based intrapartum care practices and inform clinical protocols for women receiving epidural analgesia.",[559],"Labor (Obstetrics)--Complications",[550,561,562,563,564,565,566,567],"Scheduled positioning","Primiparous women","Randomized controlled trial","Non-invasive intrapartum intervention","Maternal labor outcomes","Neonatal outcomes","Epidural Analgesia","2025-12-31",{"date":570,"type":39},"2026-01-12",{"date":481,"type":23},{"date":302,"type":23},{"name":543,"class":130},{"id":575,"slug":576,"hasResults":12,"nctId":577,"briefTitle":578,"officialTitle":578,"acronym":579,"eligibilityCriteria":580,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":581,"targetDuration":4,"studyType":24,"phases":582,"briefSummary":583,"conditions":584,"keywords":587,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":596,"lastUpdatePostDateStruct":597,"startDateStruct":599,"completionDateStruct":601,"leadSponsor":603,"locationsCount":47},"100616584","efficacy-of-scalp-block-in-managing-post-subarachnoid-hemorrhage-headache-in-critically-ill-patients-a-single-centre-randomized-controlled-trial-100616584","NCT07307508","Efficacy of Scalp Block in Managing Post Subarachnoid Hemorrhage Headache in Critically Ill Patients. A Single Centre Randomized Controlled Trial","SAH-BLOCK","Inclusion Criteria:\n\n* All adults \\> 18 years who are admitted to the Surgical Intensive Care Unit (SICU) with a confirmed diagnosis of aneurysmal subarachnoid hemorrhage, undergoing endovascular treatment of the aneurysm (coiling\u002Fflow diversion).\n\nExclusion Criteria:\n\n1. Patients with aSAH undergoing surgical craniotomy and aneurysmal clipping.\n2. Non-aneurysmal subarachnoid or other intracranial hemorrhage forms (e.g., Intracerebral hemorrhage).\n3. SICU admission Glasgow Coma Scale (GCS) of 13 or lower.\n4. WFNS Score 4 \u002F 5 or requiring mechanical ventilation for more than 24 hrs.\n5. Patients with known allergy to local anesthetics.\n6. Admission to ICU \\> 7 days after hemorrhage.\n7. Patients with a documented bleeding disorder.\n8. Patients with a history of chronic headache disorder or migraine.\n9. Pregnancy",{"count":470,"type":23},[26],"Subarachnoid hemorrhage (SAH) is a devastating neurological disorder associated with significant mortality and morbidity rates, arising not just from the hemorrhage itself but also because of the catastrophic multisystem sequelae that can accompany the condition.\n\nRupture of an intracranial aneurysm accounts for up to 85% of instances of SAH, occurring in approximately 3 to 25 people per 100,000 annually in most populations. Treatment of aneurysmal SAH (aSAH) includes prevention of re-bleeding, evacuation of space-occupying hematomas, management of hydrocephalus, and prevention of secondary cerebral insult. Severe headache is the predominant characteristic symptom of aSAH, developing almost instantaneously at ictus in 50% of cases and continuing into the first days. Its severity has a variety of physiological and psychological effects on the patient. Scalp blocks have been suggested to alleviate this headache in case series. However, there is no strong evidence supporting this intervention. In this study, we aim to assess the impact of scalp blocks on headache reduction in patients undergoing endovascular treatment of an aneurysm (coiling or flow diversion) with aneurysmal subarachnoid bleeding.",[585,586],"Aneurysmal Subarachnoid Hemorrhage (aSAH)","Headache Disorders",[588,589,590,591,592,593,594,595],"Subarachnoid Hemorrhage Headache","Aneurysmal Subarachnoid Hemorrhage","Cerebral Aneurysm","SAH-associated headache","Scalp Block","Levobupivacaine","Opioid Consumption","Neurocritical Care","2025-12-14",{"date":598,"type":39},"2025-12-29",{"date":600,"type":39},"2025-10-22",{"date":602,"type":23},"2026-12-30",{"name":543,"class":130},{"id":605,"slug":606,"hasResults":12,"nctId":607,"briefTitle":608,"officialTitle":609,"acronym":4,"eligibilityCriteria":610,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":611,"targetDuration":4,"studyType":24,"phases":613,"briefSummary":614,"conditions":615,"keywords":617,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":623,"lastUpdatePostDateStruct":624,"startDateStruct":626,"completionDateStruct":628,"leadSponsor":630,"locationsCount":47},"100540991","deprescribing-intervention-for-patients-with-chronic-kidney-disease-100540991","NCT06324045","Deprescribing Intervention for Patients With Chronic Kidney Disease","Development and Evaluation of a Multidisciplinary Team Delivered Deprescribing Intervention for Patients With Chronic Kidney Disease in Qatar: A Randomized Controlled Trial","Inclusion Criteria:\n\nPatients who are:\n\n* diagnosed with ESRD receiving hemodialysis treatment or pre-dialysis patients who are followed up at a low clearance clinic.\n* receiving treatment at one of the ambulatory kidney centers in Qatar for at least two months.\n* able to communicate in Arabic and\u002For English.\n\nExclusion Criteria:\n\n* Unstable or has a psychiatric condition.\n* Presents with uncontrolled behaviors or exit-seeking behaviors (i.e., seeking to leave the premises out of confusion, frustration, or anger).\n* Critically ill patients, pregnant women, children, mentally ill, dementia, and unconscious patients.\n* Patients with limited life expectancy (less than 6 months).",{"count":612,"type":23},424,[26],"Chronic Kidney Disease (CKD) is recognized as a leading health problem globally. It is associated with multiple consequences such as cardiovascular diseases, infections, reduced cognitive function, and higher mortality rates. In Qatar, it is estimated that 13% of the population suffers from CKD. Management of CKD is associated with polypharmacy (the use of multiple medications), which burdens the patients and leads to adverse health and economic outcomes. As documented by previous studies, CKD setting is associated with a high medication burden, which leads to non-adherence, reduced quality of life, and other negative sequelae. These consequences can be minimized or averted by implementing a deprescribing program. Deprescribing is defined as the supervised process of intentionally stopping a medication, altering the dose or introducing a safer alternative to improve a person's clinical and quality of life outcomes. Previous deprescribing initiatives in inpatient and outpatient hospital settings were successfully implemented.\n\nIn general, there are limited deprescribing initiatives in CKD settings. There is a need to provide evidence of the impact of deprescribing programs on improving clinical and economic outcomes in this setting. In Qatar, there is no evidence of the effectiveness of implementing deprescribing programs in clinical settings. Therefore, we have built a team of researchers, clinicians, and stakeholders, and initiated a collaboration with deprescribing experts to fit into the Qatar healthcare system. This project aims to initiate a deprescribing multidisciplinary team and to evaluate the impact of providing such services on the clinical and economic outcomes among CKD patients in Qatar using a randomized controlled trial approach. The findings could have a potential positive impact on the professional practice and patient safety represented by health and economic outcomes.",[616],"Chronic Kidney Diseases",[618,619,620,621,622],"Deprescribing","Inappropriate polypharmacy","Treatment burden","Multidisciplinary","Clinical pharmacy","2025-09-26",{"date":625,"type":39},"2025-10-01",{"date":627,"type":39},"2024-02-19",{"date":629,"type":23},"2026-03",{"name":543,"class":130},{"id":632,"slug":633,"hasResults":12,"nctId":634,"briefTitle":635,"officialTitle":636,"acronym":637,"eligibilityCriteria":638,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":639,"targetDuration":4,"studyType":24,"phases":641,"briefSummary":642,"conditions":643,"keywords":645,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":647,"lastUpdatePostDateStruct":648,"startDateStruct":649,"completionDateStruct":651,"leadSponsor":653,"locationsCount":654},"100590093","an-online-physical-activity-coaching-intervention-for-people-with-pd-in-qatar-100590093","NCT06962930","An Online Physical Activity Coaching Intervention for People With PD in Qatar","A Pilot RCT of a Remote Physical Activity Coaching Intervention to Promote Engagement in Physical Activity for People With Parkinson's Disease in Qatar","EQP","Inclusion Criteria:\n\n1. Age above 18 years.\n2. Successful completion of Physical Activity Readiness Questionnaire (PAR-Q), or medical clearance from a neurologist.\n3. Ambulatory for indoor and outdoor mobility with or without an assistive device but without physical assistance.\n4. A neurologist-confirmed diagnosis of PD.\n5. Ability to follow study-related commands.\n\nExclusion Criteria:\n\n1. Musculoskeletal injury or a medical condition that would prevent safe participation in an exercise program including failure to pass the PAR-Q test.\n2. The presence of any other neurological conditions.\n3. Acute illness or injury that prevents participation in the intervention.",{"count":640,"type":23},40,[26],"Regular exercise can improve function and quality of life as well as have other positive behavioral and health-related benefits in people Parkinson's disease (PD). Despite the benefits, insufficient exercise is common among PD individuals, often due to common barriers, emphasizing the importance of empowering individuals with adequate knowledge and self-management skills.\n\nThis project aims to develop \"Engage-Qatar PD,\" an online physical activity self-management program for people with PD in Qatar. Engage-Qatar PD will be grounded in a previously developed coaching intervention used in people with Huntington's disease (Engage HD) and people with PD. The main focus of this project will be the development work to adapt this intervention for online delivery for people with PD and within the Qatari context.\n\nThis development stage will entail participatory design, in which users will be actively involved as co-designers to ensure fully the required cultural adaptations. Following this development phase, a pilot randomized controlled trial will be conducted to assess the feasibility, acceptability, and potential benefits of the developed intervention.\n\nThe innovative approach proposed for this project would have wide-reaching impact, advancing the development of new therapeutic options. It will deliver a realistic, culturally adapted therapeutic option for people with PD in Qatar that has the potential to be implemented in a variety of healthcare settings and other countries in the region. Importantly, future work could replicate this program in a larger cohort of individuals with other neurodegenerative diseases and extend this work to other countries in the region.",[644],"Parkinson Disease",[646],"PD: Parkinson's Disease PA: Physical Activity NDD: Neuro Degenerative Disease QRI: Qatar Rehabilitation Institute","2025-09-23",{"date":539,"type":39},{"date":650,"type":39},"2025-09-10",{"date":652,"type":23},"2026-09-10",{"name":77,"class":46},3,{"id":656,"slug":657,"hasResults":12,"nctId":658,"briefTitle":659,"officialTitle":660,"acronym":4,"eligibilityCriteria":661,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":166,"enrollmentInfo":662,"targetDuration":4,"studyType":24,"phases":664,"briefSummary":665,"conditions":666,"keywords":668,"overallStatus":299,"whyStopped":4,"lastUpdateSubmitDate":675,"lastUpdatePostDateStruct":676,"startDateStruct":678,"completionDateStruct":680,"leadSponsor":681,"locationsCount":47},"100605599","the-effectiveness-of-occupation-based-bilateral-arm-training-on-motor-functions-and-activity-participation-among-stroke-survivors-during-inpatient-rehabilitation-100605599","NCT07164612","The Effectiveness of Occupation-based Bilateral Arm Training on Motor Functions and Activity Participation Among Stroke Survivors During Inpatient Rehabilitation.","The Effectiveness of Occupation-based Bilateral Arm Training on Motor Functions and Activity Participation Among Stroke Survivors During Inpatient Rehabilitation. A Randomized Control Trial","Inclusion Criteria:\n\n1. Diagnosed with first ischemic or hemorrhagic stroke by medical physician\n2. Stroke onset ≤ 6 months\n3. Both males and females with age 18-65 years\n4. Cognitive functions within normal and mild deficit (MMSE ≥ 22)\n5. With arm and hand upper extremity Brunnstrom stage of \\>3\n6. Free of any other neurological diseases.\n\nExclusion Criteria:\n\n1. participants with previous stroke\n2. musculoskeletal disease or sever pain affecting the upper extremities\n3. participant who have taken part in another rehabilitative research\n4. sever visual neglect or visual field deficit.",{"count":663,"type":23},150,[26],"People with stroke often experience limitations in motor functions and activity participation. Occupation-based bilateral upper limb training (OBBT) using occupations as meaningful daily activities, and as part of the therapy. The activities in OBBT are tailored to the patient's life with the goal of boosting motivation and engagement to enhance activity performance and participation. This study is a randomized control trial that aims to explore the effect of OBBT along with the conventional therapy in comparison with the conventional therapy alone on motor functions and activity participation among stroke survivors in inpatient rehabilitation setting. This study will be conducted in Qatar Rehabilitation Institute, Hamad Medical Corporation, Doha, Qatar. Participants will be allocated randomly to either the OBBT group or the conventional therapy group. Participants in the OBBT group will receive 30 minutes OBBT program in addition to conventional therapy (90 minutes). Intervention sessions will be conducted 5 times per week over 6 weeks. The participants in the conventional therapy group will receive only the conventional therapy (90 minute). All participants will be assessed using the outcome measure immediately the day after completing the last intervention session at 4th week and 6th week.",[667],"Stroke",[667,669,670,671,672,673,674],"Occupations","Occupation-based intervention","Occupational Therapy","Motor Activity","Motor Skills","Patient Participation","2025-09-16",{"date":677,"type":39},"2025-09-22",{"date":679,"type":23},"2025-09",{"date":184,"type":23},{"name":543,"class":130},""]